Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK statement in response to OFT Statement of Objections
GSK supports fair competition and we very strongly believe that we acted within the law, as the holder of valid patents for paroxetine
-
FDA Advisory Committee recommends approval of BREO(TM) ELLIPTA(TM) for the treatment of COPD
GSK & THRX announced that PADAC voted that the efficacy and safety data evidence to support approval of BREO™ ELLIPTA™
-
GSK announces first four-strain seasonal influenza vaccine granted marketing authorisation in Germany and the UK
GSK has announced the marketing authorisation of its quadrivalent (four-strain) influenza vaccine in Germany and the UK.
-
GlaxoSmithKline announces start of phase III study of Benlysta® (belimumab ) in patients with vasculitis
GSK announced the start of a Phase III study to evaluate Benlysta® (belimumab) in patients with ANCA - a condition involving inflammation
-
Regulatory update: GlaxoSmithKline receives complete response from FDA for candidate pandemic H5N1 adjuvanted influenza vaccine
GSK announced today that it has received a Complete Response letter from the FDA .
-
GSK publishes 2012 Corporate Responsibility report
Report sets out 23 forward-looking commitments to help measure future performance
-
$500,000 Endowment Gift from The GlaxoSmithKline Foundation Expands Program to Help Patients with Cancer and their Families at The Children’s Hospital of Philadelphia
The Children’s Hospital of Philadelphia is proud to announce a $500,000 gift from the GSK Foundation.
-
Young scientists challenged by GSK and McLaren to help drive science behind Formula 1™
GSK and the McLaren Group announce new science education initiative to inspire young people into science and engineering careers
-
Regulatory update – GSK announces regulatory submission for albiglutide in Europe
GSK today announced the submission of a MAA for albiglutide, with the proprietary name EPERZAN, to the European Medicines Agency (EMA).
-
ViiV Healthcare presents data from Phase III study of dolutegravir vs raltegravir in treatment-experienced adults with HIV-1
ViiV present 24-week interim results from Phase III SAILING study at the 20th Conference on Retroviruses and Opportunistic Infections (CROI)
-
ViiV Healthcare announces a voluntary licence agreement with the Medicines Patent Pool to increase access to HIV medicines for children
Agreement brings the number of voluntary licences granted by ViiV Healthcare to 14.
-
GSK and Theravance announce FDA acceptance of New Drug Application (NDA) submission in the US for ANORO ELLIPTATM for COPD
GSK & THRX announced NDA for LAMA/LABA combination medicine, UMEC/VI, for patients with COPD has been accepted by the FDA.
-
ViiV Healthcare announces FDA priority review designation for dolutegravir as a potential treatment for HIV infection
ViiV announced that the FDA has granted a priority review designation to dolutegravir submitted for the treatment of HIV infection.
-
Regulatory update – GSK announces European submission for MEK monotherapy and BRAF/MEK combination therapy in metastatic melanoma
GSK announced submission of a Marketing Authorisation Application to EMA for MEK with BRAF for the treatment of adult patients with melanoma
-
Results announcement for the fourth quarter 2012
GSK delivers 2012 core EPS of 112.7p and returns £6.3bn to shareholders
-
GSK increases stake in its publicly-listed Consumer Healthcare subsidiary in India to 72.5 per cent
GSK announced it has successfully increased its publicly-listed Consumer Healthcare subsidiary in India, from 43.2% to 72.5%
-
GSK announces support for AllTrials campaign for clinical data transparency
Campaign calls for full disclosure of clinical trial results and clinical study reports to help drive scientific understanding.
-
GlaxoSmithKline starts Phase III study to test combined BRAF/MEK inhibition in patients with BRAF positive melanoma following surgery
GSK today announced the start of COMBI-AD, a Phase III study evaluating the combination of dabrafenib, its BRAF inhibitor and trametinib.
-
GSK response to news article in The Guardian on UK legal proceedings related to Avandia (rosiglitazone)
Responding to an article in The Guardian legal proceedings related to our type 2 diabetes medicine Avandia (rosiglitazone),
-
GSK and Biological E. announce joint venture to develop combination vaccine for India and other developing countries
GSK & Biological E. announced an agreement for development of a paediatric vaccine to help protect children in India from polio
